Our Company
Softhale is a Belgium based pharmaceutical company focused on the development of pharmaceutical products, delivered by our next generation Soft Mist Inhalation (SMI) device to the lungs. Softhale is currently designing and creating a propellant-free, purely mechanical device to be used for worldwide generic and non-generic pharmaceutical development and approval processes, offering innovative as well as cost-optimized device components.
Our Product
Our next generation SMI devices incorporate a proprietary set of technical configurations to spray a propellant-free liquid formulation in a highly efficient way. Our technology creates an ultra-fine mist using a mechanically-driven impinging working principle, offering a variety of patient benefits:
They help the medication pass the natural curve of the throat
They give users time to naturally breathe in the medication
They help users get the medication deep into their lungs
Our Journey
In 2012, the founding members of Softhale met and started their conceptual work on a new generation Soft Mist Inhaler (SMI). The team had proven expertise in microfluidic, medical device, pharmaceutical and business development competencies, and the collaboration resulted in a business concept to start a pharmaceutical company. The first patent was filed by the group in 2013.
The team then conducted concept validation work and initial freedom-to-operate analysis, followed by the creation of a business plan. This plan – coupled with the team’s strong background – helped Softhale raise seed funding, leading to early stage proof-of-concept work in 2014-2015.
Since then, the Softhale team has successfully expanded collaborations across geographies, attracting series of funding and investing on a proprietary, innovative approach to inhalation therapy. This led to a successful Series A round, a more than €1 million grant and a first customer-funded proof-of-concept study in 2016.
Softhale NV was established in Diepenbeek, Belgium in 2016 and development activities related to our proprietary next generation SMI intensified.
News
Softhale NV announces New Board Member
We are delighted to welcome Mr. Nevan Charles Elam, J.D., on our Board. He has a rich background in management, operations, consulting, finance, and corporate law in combination with long term experiences in executive roles in pharmaceutical and medical device companies.
Jan-Torsten Tews joins Softhale NV as Chief Executive Officer
I feel privileged and honoured to join Softhale and its proprietary unique inhalation technology at this exciting time.
Get to know us
Softhale is a pharmaceutical company which develops inhalable therapeutics, based on our next generation Soft Mist Inhaler (SMI) device. Our primary focus is on the development of improved treatment options for the growing number of asthma and COPD patients worldwide. At the same time, we also explore tailored inhalation products outside the prescription driven market with our partners.